Therefore, in our current study, we used the ASXL1G710X mutant KBM5 CML cell line and the CRISPR/Cas9 homozygous corrected isogenic cells to evaluate the effects of the ASXL1 mutation on gene expression, chromatin accessibility, and cytosine methylation, and to correlate these findings to functional responses to VEN and AZA. The gene discussed is ASXL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.